Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 13/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 13/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 12/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.83 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | GMNN | O75496 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rilmenidine SCHEMBL15516636 | 0.91 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| Rilmenidine SCHEMBL114420 | 0.91 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| SCHEMBL6369410 | 0.83 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| SCHEMBL6367795 | 0.83 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| SCHEMBL6367792 | 0.83 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| Rilmenidine SCHEMBL1231349 | 0.81 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| SCHEMBL11137918 | 0.79 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| Rilmenidine SCHEMBL30892124 | 0.78 | CYP3A4 (1.00) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| Rilmenidine SCHEMBL6373730 | 0.78 | ADRA2A (0.73) | ADRA2AADRA2BADRA2CADRA1ANISCH | |
| SCHEMBL11140210 | 0.77 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1ANISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20050119461-A1 | Novel receptor, and compounds which bind thereto | THE UNIVERSITY OF MELBOURNE | 2005-06-02 | — | — | US | disclosed |
| EP-1044194-A4 | RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS | UNIV MELBOURNE (AU) | 2002-01-09 | — | — | EP | disclosed |
| EP-1044194-A1 | RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS | THE UNIVERSITY OF MELBOURNE (AU) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024411-A1 | RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS | THE UNIVERSITY OF MELBOURNE (AU) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119461-A1 | Novel receptor, and compounds which bind thereto | GPR27, GPR174, GPR52 | ADRA2A 137/4885ADRA2B 98/4885ADRA2C 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.